130 related articles for article (PubMed ID: 36369228)
1. HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 gallbladder cancer.
Kwon CH; Seo HI; Kim DU; Han SY; Kim S; Lee SJ; Jeon DY
Eur J Surg Oncol; 2023 Feb; 49(2):392-398. PubMed ID: 36369228
[TBL] [Abstract][Full Text] [Related]
2. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
3. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
4. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
[TBL] [Abstract][Full Text] [Related]
5. A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status.
Yoshida H; Shimada K; Kosuge T; Hiraoka N
Virchows Arch; 2016 Apr; 468(4):431-9. PubMed ID: 26758058
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
7. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma.
Albrecht T; Rausch M; Roessler S; Geissler V; Albrecht M; Halske C; Seifert C; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil-Warth A; Busch E; Köhler B; Rupp C; Weiss KH; Springfeld C; Röcken C; Schirmacher P; Goeppert B
Virchows Arch; 2020 Jun; 476(6):871-880. PubMed ID: 31838585
[TBL] [Abstract][Full Text] [Related]
8. Estimating the influencing factors for T1b/T2 gallbladder cancer on survival and surgical approaches selection.
Cao J; Yan J; Hu J; Zhang B; Topatana W; Li S; Chen T; Jeungpanich S; Lu Z; Peng S; Cai X; Chen M
Cancer Med; 2023 Aug; 12(16):16744-16755. PubMed ID: 37366278
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer.
Shukla P; Mishra K; Shukla R; Vishwakarma R; Kumari N; Krishnani N; Behari A; Kapoor VK
J Cancer Res Ther; 2024 Jan; 20(1):349-357. PubMed ID: 38554345
[TBL] [Abstract][Full Text] [Related]
10. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
11. Validation of the oncologic effect of hepatic resection for T2 gallbladder cancer: a retrospective study.
Cho JK; Lee W; Jang JY; Kim HG; Kim JM; Kwag SJ; Park JH; Kim JY; Park T; Jeong SH; Ju YT; Jung EJ; Lee YJ; Hong SC; Jeong CY
World J Surg Oncol; 2019 Jan; 17(1):8. PubMed ID: 30616645
[TBL] [Abstract][Full Text] [Related]
12. Incidental gallbladder cancer during laparoscopic cholecystectomy: managing an unexpected finding.
Cavallaro A; Piccolo G; Panebianco V; Lo Menzo E; Berretta M; Zanghì A; Di Vita M; Cappellani A
World J Gastroenterol; 2012 Aug; 18(30):4019-27. PubMed ID: 22912553
[TBL] [Abstract][Full Text] [Related]
13. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Oncologic Outcomes for T2 Gallbladder Cancer According to the Type of Surgery Performed and the Optimal Timing for Sequential Extended Cholecystectomy.
Oh MY; Kim H; Sohn HJ; Lee S; Lee M; Kim HS; Han Y; Kwon W; Jang JY
J Gastrointest Surg; 2022 Aug; 26(8):1705-1712. PubMed ID: 35641810
[TBL] [Abstract][Full Text] [Related]
15. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
16. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
18. HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma.
Chen L; Xu L; Shen L; Luo R; Jiang D; Wang Y; Li W; Hou Y
Front Genet; 2021; 12():831318. PubMed ID: 35265100
[TBL] [Abstract][Full Text] [Related]
19. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
20. Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer.
Hryciuk B; Pęksa R; Bieńkowski M; Szymanowski B; Radecka B; Winnik K; Żok J; Cichowska N; Iliszko M; Duchnowska R
Sci Rep; 2020 Feb; 10(1):1871. PubMed ID: 32024900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
